当前位置: 首页 > 期刊 > 《中国健康月刊·B版》 > 2012年第1期 > 正文
编号:12143472
比索洛尔对慢性心力衰竭的临床疗效及心功能的影响
http://www.100md.com 2012年1月1日 杨兰
第1页

    参见附件。

     【摘要】目的 探讨比索洛尔治疗慢性心力衰竭的临床疗效,进一步观察其对CHF患者心功能的影响。方法 将我院2008年12月至2010年12月收治的76例慢性心力衰竭患者随机进行分组,治疗组和对照组各38例,两组均常规进行抗心衰治疗,其中治疗组在上述治疗的基础上给予比索洛尔,比较观察两组患者疗效及治疗前后的心功能变化。结果 治疗组的总有效率为92.1%,对照组总有效率为78.9%,两组总有效率分别比较,差异有统计学意义(P<0.05)。治疗6个月后,两组的左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均较治疗前有明显改善,且治疗组较对照组明显改善, 差异有统计学意义(P<0.05)。结论 比索洛尔对慢性心力衰竭疗效确切,能有效的改善患者心功能,值得临床推广和应用。

    【关键词】慢性心力衰竭 比索洛尔 临床疗效 心功能

    中图分类号:R541.6 文献标识码:A 文章编号:1005-0515(2012)1-024-02

    Effect of Bisoprolol on the clinical efficacy of chronic heart failure and cardiac function

    【Abstract】Objective Bisoprolol in patients with chronic heart failure clinical efficacy, further observation of their cardiac function in patients with CHF. Methods to our hospital from December 2008 to December 2010 admitted 76 patients with chronic heart failure patients randomized to group, treatment group and control group 38 cases, two were routine anti-heart failure therapy, the treatment group in the above treatment given on the basis of Bisoprolol were observed comparing the efficacy and cardiac function before and after treatment. Results The total effective treatment group was 92.1% in the control group, the total effective rate was 78.9%, total effective rate of the two groups, the difference was statistically significant (P <0.05). After 6 months of treatment, both groups left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD) was significantly improved compared with before treatment, and the treatment group than in the control group improvement, the difference was statistically significant (P <0.05). Conclusion Bisoprolol is effective in chronic heart failure, which can effectively improve cardiac function and is worthy of promotion and application.

    【Keywords】Chronic heart failure Bisoprolol clinical efficacy heart function

    慢性心力衰竭(CHF)是各种心脏疾病发展到终末阶段的共同表现, β - 受体阻断剂可显著改善心力衰竭患者的心功能和逆转心力衰竭时心脏重构过程[1]。目前新的β - 受体阻断剂比索洛尔的治疗研究已广泛应用于临床。 本研究旨在探讨比索洛尔治疗慢性心力衰竭的临床疗效,进一步观察其对CHF患者心功能的影响,现报道如下:

    1 资料与方法

    1.1 一般资料 选择我院2008年12月至2010年12月间我院收治的慢性心力衰竭患者76例, 符合美国心脏病协会标准[2]。排除病态窦房结综合症HR<50次/min;II度以上房室传导阻滞;肾功能受损 ......

您现在查看是摘要介绍页,详见PDF附件(2595kb)